Instrument Inactif

Communiqués Children's Internet Inc Other OTC

Actions

US16875X3035

Equipement, fournitures et distribution médicale

Communiqués

11/02	CS Group (OTCQB: CSDX) Appoints Shah Teelani & Associates, a Dubai-Based PCAOB Auditor, to Consolidate All 2025 Financial Statements for CSDX, CS Interpharm GT LLC and CS Diagnostics Pharma GmbH	AQ
29/01	CS Group (OTCQB: CSDX) Secures Strategic Manufacturing Partnerships, Accelerating Global Commercial Launch of MEDUSA SDP Hygiene Products	AQ
27/01	MedTech: CS Diagnostics (OTCQB: CSDX): at the Crossroads of Infection Control and Oncology Innovation	AQ
21/01	CS Group (OTCQB: CSDX) Announces Multi-Channel Sales Model, Global Logistics Partners, and Sustainable Innovation Roadmap for MEDUSA SDP	AQ
13/11	CS Diagnostics Corp. (OTCQB: CSDX) Aligns Capital and Structure for 2026 Expansion	AQ
24/06/25	CS Diagnostics Corp. to Present at the Small Cap Growth Virtual Investor Conference June 26th	AQ
22/04/25	CS Group Announces the Valuation of MEDUSA Surface Disinfectant at USD 513 Million	AQ
15/04/25	CS Diagnostics Corp. is Entering into a $5 Million Loan Agreement with SAN ART CAPITAL SAS	AQ
12/03/25	OTCQB-CSDX Appoints Lachman Consultants for CS-Protect Hydrogel FDA Approval	AQ
21/01/25	CS Diagnostics Corp. Announces U.S. Launch of MEDUSA	BU
05/08/24	CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024	AQ
21/11/22	FLASHZERO CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
21/11/22	FLASHZERO CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION OR PLAN OF OPERATIONS (form 10-K)	AQ
18/11/22	FLASHZERO CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q/A)	AQ
17/11/22	FLASHZERO CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
05/06/22	FlashZero : Supplemental disclosure - Name Change	PU
30/11/-1	CS Interpharm and CS Diagnostics Pharma Complete Conversion of Preferred Shares to Common Stock, Strengthening CSDX's Path to Consolidated Financial Reporting	AQ
30/11/-1	CS Diagnostics Corp. Launches Regulation D, Rule 506(c) Investment Offering	AQ
30/11/-1	CS Diagnostics Corp. (OTCQB: CSDX) Accelerates Global Expansion with Key Regulatory Milestones and Record Growth	AQ
30/11/-1	CS Diagnostics Corp. Submits Patent Application For CS-Protect Hydrogel in the US Market	AQ
30/11/-1	CS Diagnostics Corp. Submitted Final Form-10 Registration Statement Draft to the processing team for preparation of Edgardization and filing with the U.S. Securities and Exchange Commission ("SEC")	AQ
30/11/-1	CS Group Announces Strategic MOU Between CS Interpharm and Gulf Center Group for Customized Manufacturing Collaboration	AQ
30/11/-1	CS Diagnostics Corp. CSDX to Present at the Small Cap Growth Virtual Investor Conference on June 26, 2025 at 12:30pm EDT	AQ